http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0151524-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bbb7c566de48ddc2f6ab493710ddc328 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06026 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0012 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6951 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B30-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715 |
| filingDate | 2001-01-12^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f6fe0df016cd470889782c7209df750 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fb09d1f2338466898ba905899c7ee6a |
| publicationDate | 2001-07-19^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-0151524-A1 |
| titleOfInvention | Cyclodextrin dimers with spacers having peptide structures for encapsulation of pharmaceutically active substances with potential high side-effects |
| abstract | A ridgidly spaced, cyclodextrin dimers having a preselected breaking point within the spacer sequence so as to controllably release the active pharmaceutically active substance only after it reaches the desired treatment site is described. These preselected breaking points are stable in blood but are cleavable within cells. In preferred embodiments, the cyclodextrin-pharmaceutically active substance complex is targeted to specific sites via incorporation of specific antibodies for the targeted sites, typically by complexing a biotin-avidin system to specific antibodies which thereby targets the complex to a specific site. Once at the site as the complex is taken up into the cell the preselected break point is cleaved and the encapsulated pharmaceutically active substance becomes available for action within the targeted cell. This approach permits the use of highly effective and efficient pharmaceutically active substances, whose safety restricts use to last chance efforts or which are unable to qualify for human use due to their potential side effects. In a preferred embodiment peptide structures are used as part of the spacers between bridged cyclodextrins. The cyclodextrin oligomers are complexed with pharmaceuticals with potential high side effects to safely, efficiently achieve the therapeutic action desired. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2170054-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005054303-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1309330-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005054303-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7781417-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2862649-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1309330-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2170054-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111217939-A |
| priorityDate | 2000-01-13^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 69 of 69.